IDE849

Recent news mentioning IDE849

• 2026-08-31 — IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer

Appears alongside

• IDEAYA
• FDA
• DLL3
• TOP1
• ADC

Browse the full archive →